Literature DB >> 26210453

Downregulation of miRNA-30c and miR-203a is associated with hepatitis C virus core protein-induced epithelial-mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells.

Dongjing Liu1, Jilin Wu2, Meizhou Liu3, Hui Yin4, Jiantai He1, Bo Zhang5.   

Abstract

Hepatitis C virus (HCV) Core protein has been demonstrated to induce epithelial-mesenchymal transition (EMT) and is associated with cancer progression of hepatocellular carcinoma (HCC). However, how the Core protein regulates EMT is still unclear. In this study, HCV Core protein was overexpressed by an adenovirus. The protein levels of EMT markers were measured by Western blot. The xenograft animal model was established by inoculation of HepG2 cells. Results showed that ectopic expression of HCV core protein induced EMT in L02 hepatocytes and HepG2 tumor cells by upregulating vimentin, Sanl1, and Snal2 expression and downregulating E-cadherin expression. Moreover, Core protein downregulated miR-30c and miR-203a levels in L02 and HepG2 cells, but artificial expression of miR-30c and miR-203a reversed Core protein-induced EMT. Further analysis showed that ectopic expression of HCV core protein stimulated cell proliferation, inhibited apoptosis, and increased cell migration, whereas artificial expression of miR-30c and miR-203a significantly reversed the role of Core protein in these cell functions in L02 and HepG2 cells. In the HepG2 xenograft tumor models, artificial expression of miR-30c and miR-203a inhibited EMT and tumor growth. Moreover, L02 cells overexpressing Core protein can form tumors in nude mice. In HCC patients, HCV infection significantly shortened patients' survival time, and loss of miR-30c and miR-203 expression correlated with poor survival. In conclusion, HCV core protein downregulates miR-30c and miR-203a expression, which results in activation of EMT in normal hepatocytes and HCC tumor cells. The Core protein-activated-EMT is involved in the carcinogenesis and progression of HCC. Loss of miR-30c and miR-203a expression is a marker for the poor prognosis of HCC.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Epithelial–mesenchymal transition; Hepatitis C virus core protein; Hepatocellular carcinoma; miRNA

Mesh:

Substances:

Year:  2015        PMID: 26210453     DOI: 10.1016/j.bbrc.2015.07.107

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  HCV core inhibits hepatocellular carcinoma cell replicative senescence through downregulating microRNA-138 expression.

Authors:  Tzu-Yue Shiu; Yu-Lueng Shih; An-Chieh Feng; Hsuan-Hwai Lin; Shih-Ming Huang; Tien-Yu Huang; Chung-Bao Hsieh; Wei-Kuo Chang; Tsai-Yuan Hsieh
Journal:  J Mol Med (Berl)       Date:  2017-03-03       Impact factor: 4.599

2.  Regulation of HepG2 cell apoptosis by hepatitis C virus (HCV) core protein via the sirt1-p53-bax pathway.

Authors:  Shenghu Feng; Min Li; Jinqian Zhang; Shunai Liu; Qi Wang; Min Quan; Mengran Zhang; Jun Cheng
Journal:  Virus Genes       Date:  2015-10-12       Impact factor: 2.332

3.  miR-203a suppresses cell proliferation by targeting E2F transcription factor 3 in human gastric cancer.

Authors:  Huiqin Yang; Lixia Wang; Xiaoli Tang; Wenmei Bai
Journal:  Oncol Lett       Date:  2017-10-17       Impact factor: 2.967

Review 4.  Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison.

Authors:  Sijia Shen; Yuxin Lin; Xuye Yuan; Li Shen; Jiajia Chen; Luonan Chen; Lei Qin; Bairong Shen
Journal:  Sci Rep       Date:  2016-12-05       Impact factor: 4.379

5.  Role of microRNAs in inflammation-associated liver cancer.

Authors:  Lin Huan; Lin-Hui Liang; Xiang-Huo He
Journal:  Cancer Biol Med       Date:  2016-12       Impact factor: 4.248

6.  Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study.

Authors:  Rosina Critelli; Fabiola Milosa; Francesca Faillaci; Rosario Condello; Elena Turola; Luca Marzi; Barbara Lei; Francesco Dituri; Silvia Andreani; Pamela Sighinolfi; Paola Manni; Antonino Maiorana; Cristian Caporali; Fabrizio di Benedetto; Mariagrazia Del Buono; Nicola De Maria; Filippo Schepis; Maria-Luz Martinez-Chantar; Gianluigi Giannelli; Erica Villa
Journal:  Cell Death Dis       Date:  2017-08-24       Impact factor: 8.469

7.  Serum microRNA-30c levels are correlated with disease progression in Xinjiang Uygur patients with chronic hepatitis B.

Authors:  J Zhang; J Ma; H Wang; L Guo; J Li
Journal:  Braz J Med Biol Res       Date:  2017-05-04       Impact factor: 2.590

Review 8.  HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development.

Authors:  Devis Pascut; Minh Hoang; Nhu N Q Nguyen; Muhammad Yogi Pratama; Claudio Tiribelli
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

9.  MicroRNA-30a-3p acts as a tumor suppressor in MHCC-97H hepatocellular carcinoma cells by targeting COX-2.

Authors:  XueMei Yang; JiaLing Sun; HaiTao Sun; Bin Wen; MingJia Zhang; HaiYan An; WeiCong Chen; WenTing Zhao; XiaoDan Zhong; ChunYu He; Jie Pang; SongQi He
Journal:  J Cancer       Date:  2021-05-10       Impact factor: 4.207

Review 10.  Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.

Authors:  Wataru Okajima; Shuhei Komatsu; Daisuke Ichikawa; Mahito Miyamae; Takuma Ohashi; Taisuke Imamura; Jun Kiuchi; Keiji Nishibeppu; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2017-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.